Jump to content

Final analysis of Covaxin efficacy out; vaccine 65.2% effective against Delta variant

andhra_jp

By andhra_jp
in Discussions

 Share

Recommended Posts

andhra_jp Hero

andhra_jp

Posted
Posted

Bharat Biotech's Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.

The company on Saturday, July 3, 2021, said it concluded the final analysis of Covaxin efficacy from Phase 3 trials.

The Phase 3 trials were conducted between November 16, 2020 and January 7, 2021 with 25,798 participants who were randomised to BBV152 or placebo groups.

The preprint data of COVAXIN efficacy has not been certified by peer-review, according to Medrxiv in which thedata was published.

https://www.thehindu.com/news/national/final-analysis-of-covaxin-efficacy-out-vaccine-652-effective-against-delta-variant/article35112565.ece

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
 Share
Go to topic listing
×
×
  • Create New...